besipirdine has been researched along with Alzheimer Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blitzer, RD; Cornfeldt, M; Davis, L; Effland, RC; Haroutunian, V; Huger, FP; Klein, JT; Landau, E; Martin, LL; Olsen, GE; Petko, WW; Smith, CP; Wilker, JC; Wong, GS | 1 |
| Cornfeldt, M; Davis, L; Effland, RC; Huger, FP; Kapples, KJ; Klein, JT; Olsen, GE; Petko, WW; Smith, CP | 1 |
| Dean, R; Dileo, EM; Griffiths, L; Hintze, TH; Hsu, RS; Hubbard, JW; Natarajan, C | 1 |
| Cutler, NR; Hourani, J; Huff, FJ; Sramek, JJ; Stewart, JA; Viereck, C; Wardle, T | 1 |
| Huger, FP; Kongsamut, S; Petko, W; Smith, CP | 1 |
| Huff, FJ | 1 |
| Alter, M; Antuono, PG; Cohen, SR; Crismon, ML; Cutler, NR; Delagandara, JE; Green, RC; Huff, FJ; McDonald, MA; Reichman, WE; Shipley, JE; Zemlan, FP | 1 |
| Chesson, SM; DiLeo, EM; Effland, RC; Hsu, RS; Klein, JT | 1 |
3 trial(s) available for besipirdine and Alzheimer Disease
| Article | Year |
|---|---|
A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Pyridines | 1995 |
Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine Study Group.
Topics: Alzheimer Disease; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Indoles; Psychiatric Status Rating Scales; Pyridines; Treatment Outcome | 1996 |
A treatment and withdrawal trial of besipirdine in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Parasympatholytics; Pyridines; Time Factors | 1996 |
5 other study(ies) available for besipirdine and Alzheimer Disease
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biogenic Amines; Brain; In Vitro Techniques; Indoles; Magnetic Resonance Spectroscopy; Parasympatholytics; Pyridines; Rats; Structure-Activity Relationship | 1996 |
Substituted (pyrroloamino)pyridines: potential agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biogenic Amines; In Vitro Techniques; Mice; Pyridines; Quinuclidinyl Benzilate; Rats; Structure-Activity Relationship | 1996 |
The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey.
Topics: Administration, Oral; Alzheimer Disease; Animals; Blood Pressure; Conscious Sedation; Dose-Response Relationship, Drug; Female; Half-Life; Indoles; Injections, Intravenous; Ketamine; Macaca fascicularis; Metabolic Clearance Rate; Parasympatholytics; Pyridines; Tachycardia | 1995 |
HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes.
Topics: Alzheimer Disease; Animals; Calcium; Cerebral Cortex; In Vitro Techniques; Indoles; Male; Norepinephrine; Pyridines; Rats; Rats, Wistar; Synaptosomes; Tritium | 1994 |
Determination of HP 749, a potential therapeutic agent for Alzheimer's disease, in plasma by high-performance liquid chromatography.
Topics: Alzheimer Disease; Chromatography, High Pressure Liquid; Humans; Indoles; Male; Pyridines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1991 |